You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 西藏藥業(600211.SH)高開4.3% 投資引進俄羅斯“衞星-V”腺病毒疫苗
格隆匯 11-12 09:28
格隆匯11月12日丨西藏藥業(600211.SH)高開4.3%,報79.85元,總市值198億元。西藏藥業昨日公告,公司下屬全資子公司TopRidge Pharma Limited與俄羅斯LIMITED LIABILITY COMPANY “HUMAN VACCINE”公司就Sputnik-V vaccine(“衞星-V”新冠肺炎腺病毒疫苗)開展合作,公司獲得該疫苗在中國註冊、開發、生產、進口或商業化產品及向指定區域出口等相關權益許可權。該疫苗經過I、II期臨牀試驗,於2020年8月經俄羅斯衞生部註冊,被批准用於俄羅斯境內的人羣接種,預防新冠病毒感染,在俄羅斯已經進入到商業化市場銷售階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account